Premium
Biotransformation in vitro of the 22 R and 22 S epimers of budesonide by human liver, bronchus, colonic mucosa and skin
Author(s) -
Cortijo Julio,
Urbieta Elena,
Bort Roque,
V.castell Jose,
RuizBravo Carlos,
Martinez Jorge,
PalaciosPelaez Ricardo,
Lledó Salvador,
Morcillo Esteban J.
Publication year - 2001
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1046/j.1472-8206.2001.00005.x
Subject(s) - budesonide , biotransformation , epimer , in vitro , incubation , chemistry , metabolism , pharmacology , medicine , endocrinology , biology , biochemistry , corticosteroid , stereochemistry , enzyme
The pharmacological effects of glucocorticoids are greatly influenced by their pharmacokinetic properties. In the present report, the in vitro biotransformation of the 22 R and 22 S epimers of the topical steroid budesonide was studied in the S‐9 fraction of human liver, bronchus, skin and colonic mucosa. The disappearance of unchanged epimers of budesonide was measured during 90 min of incubation by high performance liquid chromatography. The rate of disappearance was high in human liver while little biotransformation occurred in bronchial tissue and colonic mucosa, and none was detected in the skin. A marked decay of the initial concentration of unchanged budesonide epimers was noticed after 2 h incubation in cultured human hepatocytes, while only a small decrease was observed after 24 h incubation in cultured human airway smooth muscle cells and BEAS‐2B cells. The 22 R epimer of budesonide suffered greater in vitro biotransformation than the 22 S epimer in human hepatic, bronchial and colonic tissues. These findings extend those of other studies, and confirm that the high therapeutic ratio of budesonide is due to negligible local biotransformation combined with high level of liver metabolism for locally absorbed budesonide.